Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2011 Jul 1;29 Suppl 1:A37-9. doi: 10.1016/j.vaccine.2011.04.125.

The Vaccine Formulation Laboratory: a platform for access to adjuvants.

Author information

  • 1Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland. nicolas.collin@unil.ch

Abstract

Adjuvants are increasingly used by the vaccine research and development community, particularly for their ability to enhance immune responses and for their dose-sparing properties. However, they are not readily available to the majority of public sector vaccine research groups, and even those with access to suitable adjuvants may still fail in the development of their vaccines because of lack of knowledge on how to correctly formulate the adjuvants. This shortcoming led the World Health Organization to advocate for the establishment of the Vaccine Formulation Laboratory at the University of Lausanne, Switzerland. The primary mission of the laboratory is to transfer adjuvants and formulation technology free of intellectual property rights to academic institutions, small biotechnology companies and developing countries vaccine manufacturers. In this context, the transfer of an oil-in-water emulsion to Bio Farma, an Indonesian vaccine manufacturer, was initiated to increase domestic pandemic influenza vaccine production capacity as part of the national pandemic influenza preparedness plan.

PMID:
21684427
DOI:
10.1016/j.vaccine.2011.04.125
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center